Sarepta Therapeutics SRPT
Sarepta Therapeutics Q3 FY24: revenue $467.2M; diluted EPS $0.34
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-122239
- Document
- 10-Q
- Exhibit 10.1
- Material contract
- Exhibit 10.2
- Material contract
Key figures from this report
These are the numbers Sarepta Therapeutics reported for Q3 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$467.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income$33.6MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS$0.34No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$197.9MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$70.7MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Supernus Pharmaceuticals SUPN public float $1.7B, Jun 30, 2025
- Ocular Therapeutix OCUL public float $1.6B, Jun 30, 2025
- Ligand Pharmaceuticals LGND public float $1.6B, Jun 30, 2025
- Amicus Therapeutics FOLD public float $1.7B, Jun 30, 2025
- Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025